Brief: Gracell Biotechnologies Granted FDA Orphan Drug Designation For Experimental Multiple Myeloma Therapy
19/11/2021 11:04
Nov 19 (Reuters) - Gracell Biotechnologies Inc GRCL.O :
* GRACELL BIOTECHNOLOGIES GRANTED FDA ORPHAN DRUG
DESIGNATION FOR
FASTCAR-ENABLED BCMA/CD19 DUAL-TARGETING CAR-T CELL THERAPY
CANDIDATE GC012F FOR THE TREATMENT OF MULTIPLE MYELOMA
* GRACELL BIOTECHNOLOGIES-TECH TRANSFER TO LONZA TO SUPPORT
MANUFACTURING OF GC012F IN U.S. IS CURRENTLY ONGOING, WITH U.S.
IND FILING TARGETING H1 2022
Source text for Eikon: ID:nPn29WPTfa
Further company coverage: GRCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27